Gepato-gastroenterologik tadqiqotlar jurnali 2021, №1

Тема статьи

ЕСТЕСТВЕННАЯ ИСТОРИЯ НЕАЛКОГОЛЬНОЙ ЖИРОВОЙ БОЛЕЗНИ ПЕЧЕНИ (53-58)

Авторы

Каледа С.П., Мирзакаримова Ф.Р., Бабаджанов А.С.

Учреждение

Ташкентский педиатрический медицинский институт

Аннотация

НАЖБП остается одним из наиболее распространенных заболеваний печени во всем мире, с растущей распространенностью в сочетании с эпидемией ожирения и метаболического синдрома. Данные о естественной истории, хотя и с некоторой неясностью, свидетельствуют о потенциале некоторых подмножеств НАЖБП прогрессировать до цирроза, осложнений, связанных с печенью, и смертности. В этих условиях НАЖБП оказывается грозным заболеванием, имеющим значительное клиническое бремя как для настоящего, так и для будущего.

Ключевые слова

неалкогольная жировая болезнь печени, стеатоз печени, жировая дистрофия, метаболический синдром, стеатогепатит, эпидемиология.

Литературы

1. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clinic proceedings Mayo Clinic 1980;55(7):434–438. 2. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55(6):2005–2023. 3. Мирзакаримова Ф.Р., Каледа С.П., Поликаропва Н.В., Uzbek Jornal 2021; 4. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nature reviews Gastroenterology & hepatology 2013;10(11):686–690. 5. Younossi ZM, Stepanova M, Afendy M, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clinical gastroenterology and hepatology 2011;9(6):524–530. 6. Younossi ZM, Henry L. Economic and Quality-of-Life Implications of Non-Alcoholic Fatty Liver Disease. PharmacoEconomics 2015. 10.1007/s40273-015-0316-5. 7. Charlton MR, Burns JM, Pedersen RA, et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011;141(4):1249–1253. 8. Satapathy SK, Sanyal AJ. Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease. Seminars in liver disease 2015;35(3):221–235. 9. Zhu JZ, Dai YN, Wang YM, et al. Prevalence of Nonalcoholic Fatty Liver Disease and Economy. Digestive diseases and sciences 2015;60(11):3194–31202. 10. Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129(1):113–121. 11. Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non alcoholic fatty liver disease. Journal of hepatology 2008;49(4):608–612. 12. Dunn W, Xu R, Wingard DL, et al. Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. The American journal of gastroenterology 2008;103(9):2263–2271. 13. Lazo M, Hernaez R, Bonekamp S, et al. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. Bmj 2011;343:d6891. 14. Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116(6):1413–1422. 15. Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995;22(6):1714–1723. 16. Dam-Larsen S, Franzmann M, Andersen IB, et al. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 2004;53(5):750–755. 17. Rafiq N, Bai C, Fang Y, et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clinical gastroenterology and hepatology 2009;7(2):234–238. 18. Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006;44(4):865–873. 19. Soderberg C, Stal P, Askling J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010;51(2):595–602. 20. Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Annals of medicine 2011;43(8):617–649. 21. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41(6):1313–1321. 22. Brunt EM, Kleiner DE, Wilson LA, et al. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 2011;53(3):810–820. 23. Ekstedt M, Hagstrom H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of observation. 24. Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 2015;149(2):389–97. [PMC free article] 25. Adams LA, Ratziu V. Non-alcoholic fatty liver - perhaps not so benign. Journal of hepatology 2015;62(5):1002–1004. 26. Wong VW, Wong GL, Choi PC, et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 2010;59(7):969–74. 27. Pais R, Charlotte F, Fedchuk L, et al. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. Journal of hepatology 2013;59(3):550–556. 28. McPherson S, Hardy T, Henderson E, et al. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. Journal of hepatology 2015;62(5):1148–55. 29. Singh S, Allen AM, Wang Z, et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clinical gastroenterology and hepatology 2015;13(4):643–654. 30. Powell EE, Cooksley WG, Hanson R, et al. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990;11(1):74–80. 31. Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. Journal of hepatology 2005;42(1):132–138. 32. Harrison SA, Torgerson S, Hayashi PH. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. The American journal of gastroenterology 2003;98(9):2042–7. 33. Evans CD, Oien KA, MacSween RN, Mills PR. Non-alcoholic steatohepatitis: a common cause of progressive chronic liver injury? Journal of clinical pathology 2002;55(9):689–692. 34. Fassio E, Alvarez E, Dominguez N, Landeira G, Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 2004;40(4):820–826. 35. Hui AY, Wong VW, Chan HL, et al. Histological progression of non-alcoholic fatty liver disease in Chinese patients. Alimentary pharmacology & therapeutics 2005;21(4):407–413. 36. Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. Journal of hepatology 2009;51(2):371–379. 37. McCullough AJ. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clinics in liver disease 2004;8(3):521–533. 38. Onnerhag K, Nilsson PM, Lindgren S. Increased risk of cirrhosis and hepatocellular cancer during long-term follow-up of patients with biopsy-proven NAFLD. Scandinavian journal of gastroenterology 2014;49(9):1111–1118. 39. Hui JM, Kench JG, Chitturi S, et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology 2003;38(2):420–427. 40. Sanyal AJ, Banas C, Sargeant C, et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 2006;43(4):682–689. 41. Bhala N, Angulo P, van der Poorten D, et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology 2011;54(4):1208–1216. 42. Yatsuji S, Hashimoto E, Tobari M, et al. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. Journal of gastroenterology and hepatology 2009;24(2):248–254. 43. Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002;123(1):134–140. 44. Caldwell SH, Crespo DM. The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. Journal of hepatology 2004;40(4):578–582. 45. Ong J, Younossi ZM, Reddy V, et al. Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. Liver transplantation 2001;7(9):797–801. 46. McGlynn KA, Petrick JL, London WT. Global Epidemiology of Hepatocellular Carcinoma: An Emphasis on Demographic and Regional Variability. Clinics in liver disease 2015;19(2):223–238. 47. Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. Journal of hepatology 2012;56(6):1384–1391. 48. Younossi ZM, Otgonsuren M, Henry L, et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology 2015. 49. White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clinical gastroenterology and hepatology 2012;10(12):1342–1359. 50. Kawada N, Imanaka K, Kawaguchi T, et al. Hepatocellular carcinoma arising from non cirrhotic nonalcoholic steatohepatitis. Journal of gastroenterology 2009;44(12):1190–1194. 51. Haflidadottir S, Jonasson JG, Norland H, et al. Long-term follow-up and liver-related death rate in patients with non-alcoholic and alcoholic related fatty liver disease. BMC gastroenterology 2014;14:166. [ 52. Hamaguchi E, Takamura T, Sakurai M, et al. Histological course of nonalcoholic fatty liver disease in Japanese patients: tight glycemic control, rather than weight reduction, ameliorates liver fibrosis. Diabetes care 2010;33(2):284–286. 53. Chan WK, Ida NH, Cheah PL, Goh KL. Progression of liver disease in non-alcoholic fatty liver disease: a prospective clinicopathological follow-up study. Journal of digestive diseases 2014;15(10):545–552.